Genelux (GNLX) Fireside chat summary

Introduction and agenda

• The session was hosted by a senior biotech analyst, featuring the CEO, CFO, and new Chief Medical Officer, with an agenda focused on company technology, clinical progress, and future plans.

Background and experience of the speaker

• Jason Litten, the new Chief Medical Officer, is a pediatric oncologist with 20 years in oncology drug development, 10 of which focused on immuno-oncology.

Current industry trends

• Oncolytic viruses have evolved since the first approval a decade ago, with advances in delivery, safety, and combination strategies.

• The field is moving toward multimodal therapies and backbone agents that can be combined with various treatments.